Corcept Therapeutics (NASDAQ:CORT) is one of the 17 biotechnology stocks with more than 50% upside. On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics (NASDAQ:CORT). He forecasted a price target Read More
